Director, Urologic Oncology, UAB Cancer Center
Oncology
Dr. Guru P. Sonpavde, MD
|
|
Give Review
Guru Sonpavde practices Oncology. He went to medical school at Indiana University School of Medicine. Indiana University School of Medicine is ranked 45 in research and 47 in primary care medicine Guru P. Sonpavde is a published MD as well. He has 99 publications published. The latest was: Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma.
- Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine.
- Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
- Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase ...
- Docetaxel for the treatment of bladder cancer.
- Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
- Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.
- The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and M...
- Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
- Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
- Corticosteroids in the management of prostate cancer: a critical review.
- Danger on a Half Shell: Vibrio vulnificus Septicemia.
- Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostat...
- Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
- Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.
- Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
- The preclinical activity of lenalidomide in indolent urothelial carcinoma.
- The angiopoietin-tie2 pathway is a potential therapeutic target in urothelial carcinoma.
- Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer.
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis.
- Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implicatio...
- Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
- Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
- New agents for prostate cancer.
- Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma.
- Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer.
- Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.
- Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
- Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
- Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
- Emerging drugs for urothelial carcinoma.
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
- Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis.
- Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.
- Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
- The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy.
- Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma.
- Do the Sites of Metastases Provide Additional Information Regarding Prognosis and Biology in Renal Cell Carcinoma?
- Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-base...
- Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
- Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.
- Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
- Metabolic complications with the use of mTOR inhibitors for cancer therapy.
- Meta-analysis of nephrotoxicity in patients with solid tumors treated with Cisplatin versus non-Cisplatin regimens with sub-group analyses based on renal eligibility c...
- The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma.
- HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer.
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospec...
- Management of Castrate Resistant Prostate Cancer-Recent Advances and Optimal Sequence of Treatments.
- Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Tri...
- Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
- Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy.
- Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma.
- Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical ...
- Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma.
- Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.
- Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
- Immunotherapy for castration-resistant prostate cancer.
- The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for...
- Intracranial Meningeal Carcinomatosis in Metastatic Castration Resistant Prostate Cancer: Will Extension of Survival Increase the Incidence?
- The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients.
- Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.
- Axitinib for renal cell carcinoma.
- Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
- Neoadjuvant chemotherapy preceding cystectomy for bladder cancer.
- Trial design for metastatic castration-resistant prostate cancer.
- Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
- Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.
- Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
- Patient selection for phase II trials.
- Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
- Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
- Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
- Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
- Satraplatin for the therapy of castration-resistant prostate cancer.
- Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma.
- Pazopanib for the treatment of renal cell carcinoma and other malignancies.
- Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
- The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
- Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome.
- Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
- Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
- Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
- Emerging vaccine therapy approaches for prostate cancer.
- Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
- Neoadjuvant systemic therapy for urological malignancies.
- A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.
- pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder.
- Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients.
- First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?
- Tissue-based molecular markers for bladder cancer.
- New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.
Schools
Christian Medical College Vellore Tamil Nadu Dr Mgr Medical University
Nassau County Med Center
King Edward Meml Hospital
Ind University School Med Hospital
Procedures Preformed
- Biopsy
Doctors Specialties
- Medical Genetics
- Oncology
Accepted Insurances
Education
-
Indiana University School of Medicine -
Nassau University Medical Center -
Christian Medical College Vellore
Hospital
-
Birmingham Veterans Affairs Medical Center -
University of Alabama Hospital
Drug Facts
| NPI NUMBER | 1083655716 | |
| NPPES Provider LastName | SONPAVDE | |
| NPPES Provider FirstName | GURU | |
| NPPES Provider ZIPCode | 775984219 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology | |
| Total Claim Count | 204.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 5.88 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1083655716 |
| Last Name Of The Provider | SONPAVDE |
| First Name Of The Provider | GURU |
| View All |
Similar Doctors
|
Dr. Dhatri Kodali, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mohammed Quraishi, MD
This Doctor is OpenDoctor Recommended.
|